These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 26079764

  • 1. Droxidopa (Northera) for neurogenic orthostatic hypotension.
    Med Lett Drugs Ther; 2015 Jun 22; 57(1471):92-3. PubMed ID: 26079764
    [No Abstract] [Full Text] [Related]

  • 2. Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension.
    Gupta F, Karabin B, Mehdirad A.
    Clin Auton Res; 2017 Jul 22; 27(Suppl 1):15-16. PubMed ID: 28699047
    [No Abstract] [Full Text] [Related]

  • 3. Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
    Goodman BP, Claassen D, Mehdirad A.
    Clin Auton Res; 2017 Jul 22; 27(Suppl 1):17-19. PubMed ID: 28631223
    [No Abstract] [Full Text] [Related]

  • 4. Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy.
    Goodman BP, Gupta F.
    Clin Auton Res; 2017 Jul 22; 27(Suppl 1):21-23. PubMed ID: 28631222
    [No Abstract] [Full Text] [Related]

  • 5. Effectiveness of droxidopa compared to midodrine in standing blood pressure and orthostatic tolerance in adults with neurogenic orthostatic hypotension: a systematic review protocol.
    Patrick K, Martin T.
    JBI Database System Rev Implement Rep; 2017 Sep 22; 15(9):2287-2294. PubMed ID: 28902695
    [Abstract] [Full Text] [Related]

  • 6. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
    Mathias CJ, Senard JM, Braune S, Watson L, Aragishi A, Keeling JE, Taylor MD.
    Clin Auton Res; 2001 Aug 22; 11(4):235-42. PubMed ID: 11710796
    [Abstract] [Full Text] [Related]

  • 7. Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
    Claassen D, Lew M.
    Clin Auton Res; 2017 Jul 22; 27(Suppl 1):13-14. PubMed ID: 28631224
    [No Abstract] [Full Text] [Related]

  • 8. Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials.
    Chen JJ, Han Y, Tang J, Portillo I, Hauser RA, Dashtipour K.
    Ann Pharmacother; 2018 Dec 22; 52(12):1182-1194. PubMed ID: 29972032
    [Abstract] [Full Text] [Related]

  • 9. Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?
    Kaufmann H.
    Clin Auton Res; 2017 Jul 22; 27(Suppl 1):1-3. PubMed ID: 28623419
    [No Abstract] [Full Text] [Related]

  • 10. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.
    Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, Droxidopa 302 Investigators.
    Hypertension; 2015 Jan 22; 65(1):101-7. PubMed ID: 25350981
    [Abstract] [Full Text] [Related]

  • 11. Droxidopa approved for neurogenic orthostatic hypotension.
    Traynor K.
    Am J Health Syst Pharm; 2014 Apr 01; 71(7):520. PubMed ID: 24644107
    [No Abstract] [Full Text] [Related]

  • 12. Differential diagnosis of suspected neurogenic orthostatic hypotension in a patient with Parkinson disease.
    Lew M, Kremens D.
    Clin Auton Res; 2017 Jul 01; 27(Suppl 1):5-7. PubMed ID: 28674866
    [No Abstract] [Full Text] [Related]

  • 13. Managing supine hypertension in a patient with non-diabetic autonomic neuropathy receiving droxidopa for neurogenic orthostatic hypotension.
    Vernino S, Lew M, Kremens D.
    Clin Auton Res; 2017 Jul 01; 27(Suppl 1):35-37. PubMed ID: 28623420
    [No Abstract] [Full Text] [Related]

  • 14. Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension.
    White WB, Hauser RA, Rowse GJ, Ziemann A, Hewitt LA.
    Am J Cardiol; 2017 Apr 01; 119(7):1111-1115. PubMed ID: 28159196
    [Abstract] [Full Text] [Related]

  • 15. Managing neurogenic orthostatic hypotension with droxidopa in a patient with Parkinson disease, atrial fibrillation, and hypertension.
    Mehdirad A, Karabin B, Gupta F.
    Clin Auton Res; 2017 Jul 01; 27(Suppl 1):25-27. PubMed ID: 28634637
    [No Abstract] [Full Text] [Related]

  • 16. Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease.
    Kremens D, Lew M, Claassen D, Goodman BP.
    Clin Auton Res; 2017 Jul 01; 27(Suppl 1):29-31. PubMed ID: 28674867
    [No Abstract] [Full Text] [Related]

  • 17. Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus.
    Vernino S, Claassen D.
    Clin Auton Res; 2017 Jul 01; 27(Suppl 1):33-34. PubMed ID: 28674868
    [No Abstract] [Full Text] [Related]

  • 18. Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303).
    Isaacson S, Shill HA, Vernino S, Ziemann A, Rowse GJ.
    J Parkinsons Dis; 2016 Oct 19; 6(4):751-759. PubMed ID: 27636856
    [Abstract] [Full Text] [Related]

  • 19. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.
    Kaufmann H.
    Clin Auton Res; 2008 Mar 19; 18 Suppl 1():19-24. PubMed ID: 18368303
    [Abstract] [Full Text] [Related]

  • 20. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
    Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G.
    Mov Disord; 2015 Apr 15; 30(5):646-54. PubMed ID: 25487613
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.